Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Washington Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Hazard Awareness

The legacy of general health and science information has long served as a foundation for public understanding of medical treatments and their associated risks. Within this broad domain, the dissemination of knowledge about pharmaceutical interventions has enabled patients and healthcare providers to make informed decisions. As this informational heritage evolved, it increasingly addressed the complexities of adverse effects linked to specific therapies, particularly those used in chronic disease management. One such therapy, Tysabri, has been the subject of extensive discussion due to its efficacy in treating certain autoimmune conditions, alongside a recognized risk profile that includes potential neurological complications. This established context naturally extends to a more focused concern: the occupational exposure risk for individuals who may encounter Tysabri in clinical or manufacturing settings. While the primary focus of health information has been on patient outcomes, the transition to occupational safety is a logical progression. Workers handling this biologic agent, including healthcare professionals and laboratory personnel, face distinct exposure scenarios that warrant careful consideration. The pivot from general health literacy to occupational hazard awareness underscores the need for vigilance in environments where such therapies are prepared or administered. This shift in perspective does not alter the foundational principles of risk communication but rather applies them to a different population—those whose professional duties bring them into contact with the drug, thereby necessitating a tailored approach to injury prevention and legal recourse.

Tysabri and the Risk of Progressive Multifocal Leukoencephalopathy

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC polyomavirus. The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most serious safety designation, to alert prescribers and patients to this risk. The boxed warning states that Tysabri increases the risk of PML, an infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Specific risk factors for developing PML include the presence of anti-JCV antibodies, longer duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefits when initiating or continuing treatment. Clinical trial data documented PML cases in patients receiving Tysabri. In multiple sclerosis trials, two cases of PML were observed among 1869 patients treated for a median of 120 weeks; both patients had also received interferon beta-1a (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In Crohn's disease trials, one case occurred after eight doses in a cohort of 1043 patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified thousands of adverse event reports associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they reflect the real-world experience of patients.

Clinical Evidence and Mechanistic Understanding of PML

PML is a demyelinating disease of the central nervous system. A large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024 described the clinical and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study included patients with definite or clinico-radiological diagnoses, highlighting the importance of accurate identification. Symptoms of PML can include progressive weakness, visual disturbances, cognitive decline, and coordination problems. Because PML can progress rapidly, the boxed warning instructs healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic link between Tysabri and PML involves the drug's action on the immune system. Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance against JC virus. In individuals with anti-JCV antibodies, the virus can reactivate and cause PML. The risk is highest in patients who are seropositive for JCV, have been on Tysabri for more than two years, or have previously used immunosuppressant medications. The adequacy of warnings regarding Tysabri and PML is a critical issue. The boxed warning is prominently displayed in the prescribing information, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program requires prescribers, patients, and pharmacies to enroll and comply with monitoring and education requirements. Despite these measures, some patients may develop PML without timely recognition, leading to severe outcomes.

Legal Considerations for Tysabri-Related PML Injuries

For patients who have developed PML after Tysabri treatment, legal considerations may arise. An attorney specializing in Tysabri-related PML cases can help affected individuals understand their rights. Key factors in such cases include the timeline between exposure to Tysabri and the documentation of harm. PML can occur months to years after starting therapy, and early symptoms may be mistaken for multiple sclerosis relapse. Delayed diagnosis can worsen prognosis. Patients may need to demonstrate that their PML was caused by Tysabri and that warnings were insufficient or not properly communicated. In summary, Tysabri carries a known risk of PML, a severe brain infection. The FDA has mandated a boxed warning and a restricted distribution program to mitigate this risk. However, PML remains a serious adverse event that can lead to death or permanent disability. Patients who experience PML after Tysabri treatment should seek medical care immediately and may benefit from consulting with an attorney experienced in pharmaceutical injury cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is its link to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Risk factors include the presence of anti-JCV antibodies, longer duration of therapy (especially over two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What symptoms should I watch for if I am taking Tysabri?

Symptoms of PML include progressive weakness, visual disturbances, cognitive decline, and coordination problems. If you experience any new neurological symptoms, seek immediate medical attention (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How can a Tysabri PML attorney help me?

An attorney experienced in Tysabri-related PML cases can help you understand your legal rights, evaluate whether inadequate warnings or negligence contributed to your injury, and pursue compensation for medical expenses, lost wages, and pain and suffering.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.